Aquestive Therapeutics, Inc. (AQST) Net margin 2017–2025
Aquestive Therapeutics, Inc. (AQST) net profit margin by fiscal year — reported net income divided by reported revenue.
-188.1%FY2025 · since FY2017: -13.4% → -188.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -188.1% | -111.4 pp |
| FY2024 | -76.7% | -61.1 pp |
| FY2023 | -15.6% | +98.6 pp |
| FY2022 | -114.1% | +24.7 pp |
| FY2021 | -138.8% | -17.1 pp |
| FY2020 | -121.7% | +4.3 pp |
| FY2019 | -125.9% | -34.9 pp |
| FY2018 | -91.0% | -77.7 pp |
| FY2017 | -13.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More AQST financial trends
AQST RevenueAQST Net incomeAQST Gross profitAQST Gross marginAQST Operating incomeAQST Operating marginAQST Operating cash flowAQST Free cash flowAQST Capital expendituresAQST Return on equityAQST Stock buybacksAQST Dividends paidAQST Total assetsAQST Total liabilitiesAQST Shareholders’ equityAQST overview →